Sunnybrook Research Institute

Toronto, Ontario, Canada

25 recruiting

Showing 120 of 40 trials

Recruiting
Phase 3

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled78 locationsNCT07185997
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled83 locationsNCT05538130
Recruiting
Phase 3

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,630 enrolled266 locationsNCT07213804
Recruiting
Phase 2

Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

Metastatic Prostate Cancer
University Health Network, Toronto352 enrolled2 locationsNCT05404139
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

CRC (Colorectal Cancer)
Incyte Corporation700 enrolled255 locationsNCT07284849
Recruiting
Phase 3

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Colorectal NeoplasmsNeoplasms by SiteGastrointestinal Neoplasms+7 more
Pfizer800 enrolled285 locationsNCT07222800
Recruiting
Not Applicable

Laplace Early Feasibility Study - Canada

Tricuspid Regurgitation
Laplace Interventional, Inc15 enrolled3 locationsNCT07171060
Recruiting
Phase 1Phase 2

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Amyotrophic Lateral Sclerosis(ALS)Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Regeneron Pharmaceuticals54 enrolled20 locationsNCT06351592
Recruiting
Phase 3

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled366 locationsNCT05253651
Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled281 locationsNCT06764485
Recruiting
Phase 3

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Non-small Cell Lung CancerBrain Tumor
InSightec30 enrolled13 locationsNCT05317858
Recruiting
Phase 3

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Metastatic Castration-resistant Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited520 enrolled33 locationsNCT06520345
Recruiting
Phase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence, Stress
Eli Lilly and Company1,000 enrolled137 locationsNCT07202884
Recruiting
Phase 1

A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis
Eli Lilly and Company32 enrolled10 locationsNCT07571174
Recruiting
Phase 1

A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis
Eli Lilly and Company32 enrolled10 locationsNCT07571200
Recruiting
Phase 3

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Alzheimer Disease
Bristol-Myers Squibb426 enrolled158 locationsNCT07011732
Recruiting
Phase 2Phase 3

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Metastatic Pancreatic Ductal AdenocarcinomaCachexia
Pfizer982 enrolled214 locationsNCT06989437
Recruiting
Phase 3

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled211 locationsNCT06982521
Recruiting
Phase 2

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
Protara Therapeutics131 enrolled71 locationsNCT05951179
Recruiting
Phase 1Phase 2

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Advanced Solid Tumor
Eikon Therapeutics156 enrolled57 locationsNCT06253130